IncyteMEX:INCY 84 Interest Coverage is 569.70 as of Mar. 2026, which is 154% above its 10-year median of 224.63. GuruFocus rates MEX:INCY with a GF Score™ of 84/100 and a GF Value™ of MXN1,464.02 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 377 Biotechnology companies, Incyte ranks better than 59.68% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Incyte's
Operating Income
for the
three
months ended in Mar. 2026 was MXN5,846 Mil. Incyte's Interest Expense for the
three
months ended in Mar. 2026 was MXN-10 Mil.
Incyte's interest coverage for the quarter that ended in Mar. 2026 was 569.70.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Incyte Corp has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Incyte's Interest Coverage or its related term are showing as below:
MEX:INCY'
s Interest Coverage Range Over the Past 10 Years
Min: 4.19 Med: 224.63 Max: 620.56
Current: 620.56
MEX:INCY's Interest Coverage is ranked better than 59.68% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs MEX:INCY: 620.56
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Incyte Interest Coverage Related Terms
Incyte Interest Coverage Historical Data
* Premium members only.
The historical data trend for Incyte's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MEX:INCY vs MRNA, ROIV, INSM: Interest Coverage Comparison
For the Biotechnology subindustry, Incyte's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Incyte's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Incyte's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incyte (MEX:INCY) has a Interest Coverage of 569.70 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Incyte and its competitors. This is 154% above median its historical median of 224.63. Over the past decade, Incyte's Interest Coverage has ranged from 4.19 to 620.56. According to the industry distribution chart, Incyte ranks #152 out of 377 companies in the Biotechnology industry, placing it in the top 40.3%.
Is Incyte's Interest Coverage too high?
Incyte's current Interest Coverage of 569.70 is 154% above median its 10-year median of 224.63. Over the past 10 years, this metric has ranged from a low of 4.19 to a high of 620.56. The Biotechnology industry median Interest Coverage is 106.07. Incyte's value of 569.70 is 437.1% above this industry median. Based on the distribution chart, Incyte ranks #152 out of 377 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Incyte has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Interest Coverage compare to MRNA and ROIV?
According to the Biotechnology industry distribution chart, Incyte ranks #152 out of 377 companies for Interest Coverage. This puts Incyte in the upper half of its industry. The industry median Interest Coverage is 106.07. Incyte's value of 569.70 is 437.1% above this benchmark. Historically, Incyte's own Interest Coverage has ranged from 4.19 to 620.56 over the past decade. While the company's 10-year median is 224.63 vs. the industry median of 106.07, Incyte has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Incyte's current Interest Coverage of 569.70 is 437.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Incyte and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Incyte's current Interest Coverage is 569.70, which is 154% above median its own 10-year median of 224.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,464.02, compared to a current price of MXN1,676.03 — trading 14.5% above its estimated fair value. The current Interest Coverage is 569.70, which is 154% above median its 10-year median of 224.63 and 437.1% above the Biotechnology industry median of 106.07. Incyte's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Incyte (MEX:INCY), the current Interest Coverage is 569.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Incyte (MEX:INCY) Overvalued in 2026?
Based on GuruFocus' analysis, Incyte stock appears to be overvalued.
The current stock price of MXN1,676.03 is trading 14.5% above its estimated GF Value™ of MXN1,464.02.
GuruFocus considers Incyte to be Modestly Overvalued.
Key valuation signals for MEX:INCY:
Interest Coverage: 569.70 (154% above median its 10-year median of 224.63)
GF Value™: MXN1,464.02 vs. price of MXN1,676.03 (14.5% above fair value)
Industry Position: 437.1% above the Biotechnology median (#152 of 377)
No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
84GF Score
Get the complete analysis for MEX:INCY
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INCY has been successfully added to your 
